Cravath’s New York Office Moves to Two Manhattan West
November 17, 2023
Cravath partner Faiza J. Saeed participated in The Paley Center for Media’s 2023 International Council Summit, which was held in New York from November 7‑8, 2023. In a session on November 7 entitled “Media M&A: How Modern Media Giants Are Operating in Uncertain Financial Times,” Faiza spoke with Centerview Partners LLC partner and co‑founder Blair Effron about the influence of M&A on the evolving media landscape and the future outlook of deals and deal‑making against the backdrop of technological change and disruption.
Deals & Cases
October 17, 2023
On October 17, 2023, Thermo Fisher Scientific Inc. (“Thermo Fisher”), the world leader in serving science, and Olink Holding AB (publ) (“Olink”), a leading provider of next generation proteomics solutions, announced that their respective boards of directors have approved Thermo Fisher’s proposal to acquire Olink for $26.00 per common share in cash, representing $26.00 per American Depositary Share in cash. Thermo Fisher will commence a tender offer to acquire all of the outstanding Olink common shares and all of the American Depositary Shares. The transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million. Cravath is representing Thermo Fisher in connection with the transaction.
Deals & Cases
August 04, 2023
On August 3, 2023, Hasbro, Inc., a leading toy and game company, announced that it has reached a definitive agreement to sell its eOne film and TV business to Lionsgate for approximately $500 million, consisting of $375 million in cash, subject to certain purchase price adjustments, and the assumption by Lionsgate of production financing loans. Cravath is representing Hasbro in connection with the transaction.
Deals & Cases
July 28, 2023
On July 28, 2023, Biogen Inc. (“Biogen”) and Reata Pharmaceuticals, Inc. (“Reata”) announced that they have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Cravath is representing Biogen in connection with the transaction.
Deals & Cases
May 25, 2023
On May 25, 2023, Illumina, a global leader in DNA sequencing and array‑based technologies, announced that Illumina shareholders have voted to elect eight of nine Illumina director nominees to the Board of Directors. Cravath represented Illumina in connection with these matters.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.